NAB2

CAT: 0804-HY-110174-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-110174-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
NAB2 is a neuroprotectant that targets the small GTPase Rab1a. NAB2 selectively binds to the GDP-bound form of Rab1a and protects multiple cell types from α-synuclein toxicity by increasing Rab1a expression. Rab1a regulates ER-to-Golgi trafficking and mediates endosomal trafficking events of the E3 ubiquitin ligase Rsp5/Nedd4. NAB2 stimulates ubiquitination of related proteins in a Nedd4-dependent manner and rescues α-synuclein-associated trafficking defects associated with early-onset Parkinson's disease[1][2][3].
CAS Number
[1504588-00-4]
UNSPSC
12352005
Hazard Statement
H315-H319-H335
Target
α-synuclein
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nab2.html
Purity
99.69
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C(C=C(C)C=C1)N2C3=CC=C(C(NCC4=C(C=CC=C4)Cl)=O)C=C3N=C2
Molecular Formula
C23H20ClN3O
Molecular Weight
389.88
Precautions
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362-P403+P233-P405-P501
References & Citations
[1]Tardiff DF, et al. Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science. 2013;342 (6161) :979-983.|[2]Hatstat AK, et al. Chemoproteomic-enabled characterization of small GTPase Rab1a as a target of an N-arylbenzimidazole ligand's rescue of Parkinson's-associated cell toxicity. RSC Chem Biol. 2021 Nov 9;3 (1) :96-111.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
α-synuclein

Popular Products